On Apr 3, we issued an updated research report on Medtronic plc MDT. While we are encouraged by the global acceptance of the company’s advanced therapies, its escalating costs and expenses raise concerns. The company has a Zacks Rank #3 (Hold).
Medtronic to Grow on Strong Fundamentals, High Costs a Woe
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться